Article Summary
February 11, 2021
Symptoms and Laboratory Manifestations of Mild COVID-19 in a Repatriated Cruise Ship Cohort
Among 49 passengers traveling from Uruguay to Australia on a cruise ship with high COVID-19 incidence in April 2020, 42% were asymptomatic and only 15% of symptomatic cases reported fever. Serial respiratory and rectal swabs were positive for 10% and 5% of participants, respectively, after a median of 3 weeks post-symptom onset. The authors suggest…
Lasting Antibody and T Cell Responses to SARS-CoV-2 in COVID-19 Patients Three Months after Infection
In a longitudinal study of 25 convalescent SARS-CoV-2 positive patients, approximately 65% of patients had detectable T cell responses 3-4 months post-symptom onset (PSO) despite all patients seroconverting. All patients had detectable IgG against the nucleocapsid (N) and spike (S) protein as well as detectable IgG and IgM responses against the receptor-binding domain (RBD); all…
Impact of COVID-19 Vaccination Program on Healthcare Worker Infections in an Academic Hospital
An academic hospital in Virginia reported a 25% decrease in health care worker (HCW) SARS-CoV-2 infections 6 days after beginning employee immunizations. Vaccines included both the Pfizer vaccine initiated on December 12, 2020 and the Moderna vaccine initiated on December 28, 2020. After achieving 60% vaccination coverage of the 1st dose, infections decreased by 50%….
SARS-CoV-2 Antibody Prevalence in England Following the First Peak of the Pandemic
A large serosurvey in England (REACT-2 Study) estimated the nationwide seroprevalence of SARS-CoV-2 to be 6%, corresponding to an estimated 3.4 million people with prior infection. Seroprevalence was determined from a representative cohort of over 100,000 adults (>18 years old). Prevalence was 2- to 3-fold higher among healthcare workers compared with non-essential workers, and higher…
Citywide Serosurveillance of the Initial SARS-CoV-2 Outbreak in San Francisco
[Pre-print, not peer reviewed] SARS-CoV-2 serosurveillance using remnant samples from routine blood draws in two major hospital networks in San Francisco estimated a seroprevalence of 4.2% in the period between March and June 2020. Seroprevalence was higher among those who were uninsured; individuals identifying as Hispanic, Black, or African; males; and individuals who experience homelessness….
Detection Of Genomic Variants Of SARS-CoV-2 Circulating In Wastewater By High-Throughput Sequencing
[Pre-print, not peer reviewed] Analysis of 40 Spanish wastewater samples obtained between April and October 2020 identified three variants with mutations in the spike protein not previously detected elsewhere and 7 non-synonymous spike protein mutations not previously detected in Spain. Three of these 7 mutations have been found at low frequencies in sequencing of genomes…
Imported SARS-COV-2 Variant P.1 Detected in Traveler Returning from Brazil to Italy
An imported case of the P.1 SARS-CoV-2 variant (also known as the B.1.1.28 or 20J/501Y.V3 variant) was detected in an asymptomatic passenger traveling on an indirect flight from Brazil to Italy on January 17, 2021. The case patient and his family received PCR-negative results at the departure airport in Brazil, and was tested on January…
Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
A novel SARS-CoV-2 strain was detected in 4 travelers flying from Brazil to Japan on January 2, 2021. Whole genome sequencing suggests the variant descends from the P.1 lineage with 12 nonsynonymous mutations in the receptor-binding domain (RBD) of the spike protein, including the K417T, E484K, and N501Y mutations also present in the B.1.1.7 and…
Emergence of a Novel SARS-CoV-2 Variant in Southern California
A novel variant of SARS-CoV-2 called “CAL.20C” was identified in Southern California and emerged contemporaneously with a local surge in cases. The authors define the variant on the basis of three mutations in the S-protein (S13I; W152C; and L452R) which differentiate the subclade from the 20C clade currently predominant in North America. The functional effect…
Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19
SARS-CoV-2 RNA was not detected by RT-qPCR in breast milk samples (n=37) collected from 18 women following COVID-19 diagnosis. Breast milk was collected on average 12.0 +/- 8.9 days after onset of signs and/or symptoms. In contrast, 76% and 80% of samples contained anti-SARS-CoV-2 IgA and IgG, respectively, and 62% of samples neutralized SARS-CoV-2 in…
Previous page Next page